Long-term Outcomes in Long Standing Persistent Atrial Fibrillation (LoTO_CASA_AF)

Long-term Outcomes in Long Standing Persistent Atrial Fibrillation Following Catheter Or Thoracoscopic Surgical Ablation : Extended Follow-Up Of CASA-AF Randomised Controlled Trial

Atrial fibrillation (AF) is a condition detected as an irregular heartbeat. It is the most common rhythm disturbance worldwide which can lead to significant symptoms and serious health problems (stroke and heart failure). The longer a person has AF, the more difficult it is to restore a normal heart rhythm. Those with continuous AF for longer than a year are described as having longstanding persistent AF (LSPAF). This is the most challenging type of AF to treat and medications are often not effective. Apart from medications patients with LSPAF may be offered a medical procedure to help improve their symptoms. It involves putting a flexible thin tube (catheter) into a blood vessel in the groin and up into the heart to destroy the tissue causing irregular heart beat. This procedure has modest success in improving symptoms in the long term. Recently, keyhole surgery has been used for these patients and evidence shows that it is better than the catheter procedure. However, we do not know how well people are doing beyond one year. Feedback from a patient focus group suggested that knowing the long-term results of these two procedures is important to help them make an informed choice when it comes to treatment. In this study we propose to continue monitoring patients from a randomised clinical trial (CASA AF RCT) who have already had one of the procedures. They have a small heartbeat monitor implanted under the skin with a battery life of around 3 years. We will be able to look at their heart rhythm data for the duration of this period and detect the return of the fibrillation if it happens.

Study Overview

• Status: Completed
• Conditions: Long Standing Persistent Atrial Fibrillation

Detailed Description

This study involves participants from the randomised clinical trial which was just completed (CASA AF RCT: NCT02755688; ISRCTN18250790 ). They have undergone relevant ablation procedures in a randomised fashion and completed 12 months follow up. At the last study visit they signed a consent form to confirm that they have agreed to keep implanted loop recorder for the duration of its battery life time (approximately 3 years). They have also continued to regularly transfer data from their implanted loop recorder to the secure server where it is regularly reviewed. This group of patients is now a unique cohort whose follow up data is invaluable for additional research. For this study we will ask for their written consent and apart from analysing their heart rhythm data we will arrange two hospital visits with some additional tests and completion of questionnaires.

The principal objective of the study is to compare the long-term effectiveness of thoracoscopic surgical ablation and percutaneous catheter ablation, the two procedures available for treatment of atrial fibrillation in patients with longstanding persistent AF (LSPAF). There is some evidence that thoracoscopic surgical ablation may be better than catheter ablation in keeping the patients in regular heart rhythm after a single procedure without use of antiarrhythmic drugs in short term. In this study we plan to monitor patients who have undergone these procedures for 3 years.

Our secondary objectives are focussing on patients who had more than one procedure and/or may be using medications in order to maintain regular heart rhythm during 36 months follow up.

We will therefore look at:

1. the effectiveness of a single procedure (catheter or surgical) in maintaining normal rhythm with use of antiarrhythmic drugs.
2. the effectiveness of multiple ablative procedures in maintaining sinus rhythm with and without use of antiarrhythmic drugs.

3. the proportion of patients who are still in AF but the time they spend in it is reduced by ≥75%.

   We will also want to examine:

4. patient reported change in quality of life from baseline to 24 and 36 months after ablative treatment.
5. changes in levels of serum biomarkers from baseline to 36 months and how they relate to the freedom of arrhythmia
6. health and social care resource use and associated costs from baseline to 36 months
7. the cost-effectiveness of thoracoscopic surgical ablation compared with catheter ablation and update the health economic model developed for the main study (CASA AF RCT).

Our sample size calculations show that with an expected rate of attrition of around 20% we need 94-100 study participants to show the difference in the effectiveness of the two procedure with power of 80%, p= 0.05.

Patients participating in this extended follow-up study will attend two hospital appointments to coincide with 24 and 36 months post-ablation (± 6 months). These two visits will consist of:

1. clinical examination
2. review of concurrent medications and comorbidities
3. electrocardiogram (12 lead ECG )
4. blood test for routine biochemistry and collection of a sample for biomarkers analyses
5. completion of questionnaires to assess patients' quality of life: atrial fibrillation effect on quality of life (AFEQT), EuroQol (EQ5D5L) European Heart Rhythm Association score of atrial fibrillation (EHRA),
6. Health economic questionnaire to capture repeat procedures (ablation, direct current cardioversion and AF-related emergency care)

For the duration of the extended follow-up, once a week patients will download data from their implantable loop recorders which have algorithms that are specific for atrial arrhythmias (atrial fibrillation, atrial tachycardia, atrial flutter). Patients remotely download their data to the Medtronic (MyCarelinkTM) secure server. These data will be reviewed centrally every month by a dedicated Research Fellow. Patients will be contacted monthly by telephone to ensure compliance and to discuss any rhythm abnormalities detected in these data that require review of treatment/ management. Patients will be able to contact the research team if they experience symptoms of atrial arrhythmias. The implanted loop recorder data can be interrogated remotely, and appropriate advice regarding treatment given based on data review.

• Study Type: Observational
• Enrollment (Actual): 104

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom
    • Royal Brompton and Harefield NHS Trust

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients with long standing persistent atrial fibrillation who took part in the CASA AF clinical trial and underwent one of the intervetions: catheter ablation or surgical thoracoscopic ablation. These patients have agreed to keep their implanted loop recorders and continued to dowload their data.

Description

Inclusion Criteria:

CASA-AF RCT participants who have undergone ablative procedure to treat their LSPAF, completed 12 months follow up and consented to keep their implanted loop recorders in situ with weekly data downloads.

Exclusion Criteria:

There are no exclusion criteria for this study.

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Other

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Thoracoscopic surgical ablation; Participants in CASA AF Trial who underwent thoracoscopic surgical ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.
Cather ablation; Participants in CASA AF Trial who underwent conventional catheter ablation to treat their long standing persistent AF will be asked to continue downloading the data from their implanted loop recorder, attend two hospital appointments (at 24 and 36 months post ablation) to complete questionnaires, have an ECG, a blood test and report current medications they use.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Effectiveness of a single ablative procedure	Freedom from continuous atrial arrhythmia (≥120 seconds in duration) recorded by implantable loop recorder or other clinically indicated rhythm recording device and absence of anti-arrhythmic drugs on concurrent medications form.	over the duration of the followup period (24 months)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Reduction of burden of atrial fibrillation	Proportion of patients who experience recurrence of atrial arrhythmias but are in sinus rhythm 75% of the time or more	over the duration of the followup period (24 months)
AF related quality of life	Measurement of changes in overall AFEQT scores (18 questions) and treatment satisfaction scores (2 questions) from baseline to two follow up time points	at 24 and 36 months from the ablative treatment
Quality of life assessment	EQ5D5L questionnaires (descriptive and analogue scale) will be completed at baseline and two follow up timepoints. Changes in scores on both scales will be used to assess and quantify patients' health outcome	at 24 and 36 months from the ablative treatment
Changes in concentration of serum biomarkers (pg/ml)	Serum assays for different biomarkers (pg/ml) will be performed at baseline and compared to the concentrations in samples collected at follow up visits. Increase (or decrease) of the biomarkers' concentration will be related to freedom from arrhythmia during follow up.	from baseline to 36 months after the ablative procedure

Collaborators and Investigators

• Sponsor: Royal Brompton & Harefield NHS Foundation Trust
• Collaborators: Brighton and Sussex University Hospitals NHS Trust; Liverpool Heart and Chest Hospital NHS Foundation Trust

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2020
• Primary Completion (Actual): November 15, 2021
• Study Completion (Actual): February 1, 2022

Study Registration Dates

• First Submitted: February 18, 2020
• First Submitted That Met QC Criteria: February 19, 2020
• First Posted (Actual): February 21, 2020

Study Record Updates

• Last Update Posted (Actual): May 2, 2022
• Last Update Submitted That Met QC Criteria: April 26, 2022
• Last Verified: April 1, 2022

More Information

Terms related to this study

• Keywords: atrial fibrillation; catheter ablation; implanted loop recorder; thoracoscopic surgical AF ablation
• Additional Relevant MeSH Terms: Pathologic Processes; Heart Diseases; Cardiovascular Diseases; Arrhythmias, Cardiac; Atrial Fibrillation
• Other Study ID Numbers: 271930

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No